key: cord-0966260-1xojj7zl authors: Sinnberg, T.; Lichtensteiger, C.; Hasan Ali, O.; Pop, O. T.; Gilardi, M.; Risch, L.; Bomze, D.; Kohler, P.; Vernazza, P.; Albrich, W. C.; Kahlert, C. R.; Brugger, S. D.; Abdou, M.-T.; Zinnber, C.; Tzankov, A.; Roecken, M.; Kern, L.; Brutsche, M. H.; Kalbacher, H.; Velic, A.; Macek, B.; Penninger, J. M.; Matter, M. S.; Flatz, L. title: IgA autoantibodies target pulmonary surfactant in patients with severe COVID-19 date: 2021-02-05 journal: nan DOI: 10.1101/2021.02.02.21250940 sha: 6717363ddbf5de40a9c3c8f746e843f608804c0b doc_id: 966260 cord_uid: 1xojj7zl Complications affecting the lung are hallmarks of severe coronavirus disease 2019 (COVID-19). While there is evidence for autoimmunity in severe COVID-19, the exact mechanisms remain unknown. Here, we established a prospective observational cohort to study lung specific autoantibodies (auto-Abs). Incubation of plasma from severe COVID-19 patients with healthy human lung tissue revealed the presence of IgA antibodies binding to surfactant-producing pneumocytes. Enzyme-linked immunosorbent assays (ELISA) and protein pull-downs using porcine surfactant confirmed the presence of auto-Abs binding to surfactant proteins in severe COVID-19 patients. Mass spectrometry and ELISAs with recombinant proteins identified IgA auto-Abs that target human surfactant proteins B and C. In line with these findings, lungs of deceased COVID-19 patients showed reduced pulmonary surfactant. Our data suggest that IgA-driven autoimmunity against surfactant may result in disease progression of COVID-19. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 5, 2021. ; https://doi.org/10.1101/2021.02.02.21250940 doi: medRxiv preprint The Coronavirus disease 2019 , caused by infection with severe acute respiratory 2 syndrome coronavirus 2 (SARS-CoV-2), has rapidly evolved into a global pandemic with grave 3 socio-economic implications that affects every country worldwide. 1,2 To date there have been reported 4 more than 100 million cases of infection with SARS-CoV-2 and over 2 million deaths across the 7 patients. 1 2 Clinical study design 3 In order to identify auto-Abs in patients with COVID-19 we enrolled N=46 individuals in a 4 prospective monocentric observational study and collected plasma samples. The median age was 61 5 years (interquartile range 55-70 years), and 32 (70%) were male. Patient characteristics are provided 6 in Supplementary Table 2. Patients were divided into subgroups by COVID-19 severity based on 7 clinical criteria. 29 In summary, we included 26 (57%) patients with critical, 13 (28%) with severe, and 8 7 (15%) with asymptomatic illness. For simplicity, patients with critical and severe disease will be 9 referred together as severe COVID-19. Additionally, we included plasma samples from healthy, non- We assessed the presence of autoimmune-disease specific auto-Abs in COVID-19 patients and found 1 5 several auto-Abs that were elevated in individuals suffering from severe COVID-19 compared to 1 6 asymptomatic patients (Fig. 1d) . Using the median antibody values of all cohorts, we calculated a 1 7 cumulative autoimmunity score (CAS). As expected, the CAS in severe COVID-19 patients was 1 8 significantly higher than in asymptomatic patients (P=0.02, two-tailed t-test, Figure 1e ). In line with 1 9 the literature, 14 our data showed elevated auto-Abs in severe COVID-19 compared to asymptomatic 2 0 patients, suggesting a vigorous auto-Abs response associated with disease severity. and healthy control patients with normal human alveolar lung tissue. We discovered specific binding 2 7 of IgA antibodies to distinguished areas of lung tissue (Fig. 2a) . IgG were discoverable to a lesser 2 8 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 5, 2021. ; https://doi.org/10.1101/2021.02.02.21250940 doi: medRxiv preprint extent (Supplementary Fig. 1) . Given that type II pneumocytes are the primary pulmonary target of 1 SARS-CoV-2, 30 we assessed mRNA expression from various lung alveolar cells using previously 2 published data. 31 This revealed a characteristically high gene expression of surfactant proteins C 3 (SFTPC), B (SFTPB), A1 and A2 in type II pneumocytes (Fig. 2b) . To examine, whether COVID-19 4 patients showed IgA and IgG derived autoreactivity against surfactant-producing cells, we performed 5 immunofluorescence and co-stained for surfactant protein A as a surrogate marker for type II 6 pneumocytes. This showed strong co-localization of IgA and surfactant (Fig. 2c) , and, to a lesser 7 extent, of IgG and surfactant (Supplementary Fig. 2) . Thus, our data indicate that predominantly IgA 8 auto-Abs bind to surfactant proteins in severe COVID-19 patients. In order to identify the target surfactant protein, we performed ELISA coated with poractant alfa. we identified protein components of poractant alfa using mass spectrometry, which confirmed the 1 8 presence of SFTPB and SFTPC (Fig. 3b) . To identify putative antigens, we prepared pull-down 1 9 affinity columns: here we used pooled and immobilized Ig from severe COVID-19 patients (n=14) analyzed by mass spectrometry to determine the Ig-captured proteins. Interestingly, SFTPB was the 2 2 most abundant protein with high enrichment (≥10-fold) for captured proteins from plasma of severe 2 3 COVID-19 patients (Fig. 3c) test) and for SFTPC (severe vs. asymptomatic, P=0.004) (Fig. 3d) . Conversely, they showed no 2 7 significant difference for autoreactive IgG (Supplementary Fig. 4 ). All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 5, 2021. ; https://doi.org/10.1101/2021.02.02.21250940 doi: medRxiv preprint 1 Surfactant is diminished in lungs of deceased COVID-19 patients 2 SARS-CoV-2 primarily infects cells via their angiotensin converting enzyme 2 (ACE2) receptors. 33 3 By infecting alveolar type II epithelial cells, which are rich in ACE2 receptors on their surface, 4 SARS-CoV-2 directly influences the function and production of surfactant proteins. 30 Our data of 5 auto-Abs against surfactant protein suggest an additional mechanism of surfactant disturbance. To 6 investigate, whether surfactant in lung tissue of COVID-19 patients is affected, we assessed its 7 presence in deceased COVID-19 patients with DAD and compared it to patients with non-COVID-19 8 DAD, and healthy controls. As suggested by previously reported gene expression analysis, 34 the total 9 amount of surfactant was reduced in COVID-19 patients in comparison to non-COVID-DAD as well 1 0 as to healthy controls (Fig. 3e ). In summary, we identified novel IgA-driven autoimmune response against SFTPB and SFTPC in 1 2 severe COVID-19 patients, which is associated with diminished surfactant. Our data suggest that a process control probe per sample is less than 28%, the read depth is at least 750000 and the relative 2 2 standard deviation of reads allocated to each probe within a sample is greater than 0.094. In addition, 2 3 only samples with a known postmortem interval were preserved for differential analysis. Differential vs. control patients with other DAD were modelled with a negative binomial distribution and 2 8 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 5, 2021. ; https://doi.org/10.1101/2021.02.02.21250940 doi: medRxiv preprint subjected to a Wald significance test. Prior to heatmap visualization, the normalized counts were 1 further $log_2$ transformed using a robust variance stabilization. The heatmap of genes with a | log 2 fold change | > 1 was produced with the complexHeatmap package. Column sample clusters were 3 obtained by k-means clustering with k = 2 and row gene clusters by hierarchical clustering with 4 complete linkage. Functional analysis was quantified via gene set enrichment. All genes in the 5 autoimmune panel were pre-ranked using the Wald test statistic and submitted to the entire KEGG 6 database of human pathways using the clusterProfiler package. COVID-19, blood draw at an unknown timepoint is assumed. Plasma samples were isolated from sodium-heparin whole blood (BD Vacutainer® CPT™ tubes, 2 7 Becton Dickinson, NJ). Briefly, the tubes were centrifuged at room temperature (RT) at 1650 g for 20 2 8 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 5, 2021. minutes at room temperature. The undiluted plasma was then aliquoted and stored at -80 °C for 1 subsequent analysis. patient, if the result is above (score of "1") or below (score of "0") that value. The CAE represents the 1 8 sum of those scores across all autoantibodies for any given patient. (pooled from three individuals, diluted 1:3 in PBS), and two slides with PBS only (negative controls). After washing, one of the of the control slides was then incubated with sterile PBS for 30 min at room 2 7 temperature, while the remaining three slides were incubated with anti-IgA FITC (Dako, catalog no. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Fresh frozen lung tissues were incubated with the above described patients' plasma pools diluted 1:3 Single cell RNA data analysis 1 Single-cell RNA sequencing data of healthy lungs were obtained from the LungMap project 31 via the 2 ToppCell portal (https://toppcell.cchmc.org/). Counts were normalized to log2-transcripts per million 3 (TPM) and compared across the 7 major epithelial cell types: type-1, and type-2 alveolar-, basal-, 4 ciliated-, club-, and goblet cells, as well as ionocytes. Housekeeping genes were excluded from the 5 analysis. Cell-specific genes were defined as those with overall expression log2-TPM > 5 and at least 6 4-fold higher expression in one or two particular cell types compared to all other cell types. manufacturer and packed into 15 mL empty polypropylene columns (Chromabond, Machery-Nagel). The protein content of 0.33 mL Curosurf® (poractant alfa, Chiesi Farmaceutici, Parma, Italy) was 1 8 immuno-purified after acetone precipitation in 15 mL of PBS-T per column by overnight binding at 1 9 4°C using a peristaltic pump (ISM597A, Ismatec, Wertheim, Germany) and a circuit flow rate of 0.5 2 0 mL/min, washing with 100 ml of PBS-T and elution in glycine buffer pH 2.5. immuno-purified and eluted proteins and in-gel digestion with Trypsin was conducted as described Scientific, Waltham, MA) coupled to an QExactive HF Orbitrap mass spectrometer (Thermo Fisher 2 8 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 5, 2021. ; https://doi.org/10.1101/2021.02.02.21250940 doi: medRxiv preprint rate of 200nl/min, selecting 20 most intensive peaks for fragmentation with HCD. The MS data was 3 processed with MaxQuant software suite v.1.6.7.0 45 to measure the iBAQ which was used to calculate 4 the relative protein level (riBAQ=iBAQ/(ΣiBAQ)). Database search was provided against pig 5 (121817 entries) and human (96817 entries) UniProt database using the Andromeda search engine. 46 6 7 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (2020). Rev Microbiol, doi:10.1038/s41579-020-00459-7 (2020). (2020). doi:10.1016/j.cell.2020.04.004 (2020). All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 5, 2021. Tumor. Mol Cancer Ther 19, 1173 -1182 , doi:10.1158 /1535 -7163.MCT-19-0959 (2020 . All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 5, 2021. ; J Proteome Res 10, 1794-1805, doi:10.1021/pr101065j (2011) . All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Supplementary information is available for this paper. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 5, 2021. (n=11) and other causes (n=10) reveals a clustered upregulation of genes. c, Gene set enrichment with severe COVID-19 (n=18) have significantly more IgA against SFTPB (P=0.001) and 1 significantly more IgA against SFTPC (P=0.004) than asymptomatic patients (n=6) in the blood 2 (mean with 95% CI). e, Indirect immunofluorescence with healthy lung tissue indicates reduced 3 amounts of surfactant in non-COVID-19 diffuse alveolar damage (DAD) than in COVID-19 DAD. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 5, 2021. ; https://doi.org/10.1101/2021.02.02.21250940 doi: medRxiv preprint All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 5, 2021. ; https://doi.org/10.1101/2021.02.02.21250940 doi: medRxiv preprint MaxQuant enables high peptide identification rates, individualized 1 p.p.b.-range mass accuracies and proteome-wide protein quantification Andromeda: a peptide search engine integrated into the MaxQuant environment antiphospholipid IgA-antibodies. Clin Infect Dis, doi:10.1093/cid/ciaa1496 (2020). All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Position in the Ranked List of Genes Running Enrichment Score All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted February 5, 2021. ; https://doi.org/10.1101/2021.02.02.21250940 doi: medRxiv preprint